KRd Lowers Progression Risk in High-Risk Smoldering Myeloma | IMS 2026

Dirk van Esser, a PhD candidate at Erasmus MC Cancer Institute, discusses long-term follow-up from the HOVON147/EMN15 trial in high-risk smoldering myeloma at IMS 2026 in Glasgow. The trial compared carfilzomib, lenalidomide and dexamethasone (KRd) with lenalidomide and dexamethasone (Rd). Viewers will learn how KRd led to deeper responses and a lower risk of progression to active myeloma, with manageable side effects, and what future trials of T-cell redirecting therapies may add.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:
0:00 Introduction
0:30 What is smoldering myeloma?
1:40 Trial design: KRd vs. Rd
2:05 Results: lower risk of progression
2:22 MRD negativity, the primary endpoint
2:49 Safety and side effects
3:25 Advice and what's next
3:59 What treatment did each group receive?